May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Is There a Penalty for Delayed Treatment in Ocular Hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS)
Author Affiliations & Notes
  • D.K. Heuer
    The Eye Institute, Medical College of Wisconsin, Milwaukee, WI, United States
  • E.J. Higginbotham
    Department of Ophthalmology, Maryland Center for Eye Care Associates, Baltimore, MD, United States
  • M.A. Kass
    Department of Ophthalmology and Visual Sciences, Washigton Univ., St. Louis, MO, United States
  • R.K. Parrish, II
    Bascom Palmer Eye Institute, University of Miami, Miami, FL, United States
  • M.O. Gordon
    Department of Ophthalmology, Washigton Univ., St. Louis, MO, United States
  • Ocular Hypertenstion Study Group
    Department of Ophthalmology, Washigton Univ., St. Louis, MO, United States
  • Footnotes
    Commercial Relationships  D.K. Heuer, None; E.J. Higginbotham, None; M.A. Kass, None; R.K. Parrish, II, None; M.O. Gordon, None.
  • Footnotes
    Support  EY09307
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 104. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      D.K. Heuer, E.J. Higginbotham, M.A. Kass, R.K. Parrish, II, M.O. Gordon, Ocular Hypertenstion Study Group; Is There a Penalty for Delayed Treatment in Ocular Hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS) . Invest. Ophthalmol. Vis. Sci. 2003;44(13):104.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the incidence of POAG in fellow eyes of participants in the observation group and medication group of OHTS who develop unilateral POAG. Methods: 116 participants developed unilateral POAG (35 in the medication group and 81 in the oservation group). When participants developed POAG, they were treated vigorously in both eyes. Treatment prescribed was at the discretion of the treating clinician and was not dependent upon the original randomization status. For this analysis, we excluded "concurrent" cases of POAG, which were defined as those occurring in less than 6 months of the initial POAG endpoint. Results: POAG developed 6 months or more after the initial endpoint in 1of 35 fellow eyes of participants in the medication group compared to 9 of 81 fellow eyes of participants in the observation group (rate ratio, 0.165; 95% confidence interval of 0.021 to 1.31; Mantel Haenszel log rank p-value = 0.052). Conclusion: Fellow eyes that were on treatment all along faired better over the subsequent months than did the fellow eyes from the observation group which were started on treatment only after they reached a POAG endpoint in the opposite eye. The duration of follow-up after the first eye developed POAG is still too short (median 24 months) to draw definite conclusions, but this is a thought-provoking finding. CR: None Support: NIH grants EY 09307, EY 09341 and Unrestricted Grants from Research to Prevent Blindness, Inc.  

Keywords: clinical (human) or epidemiologic studies: tre • optic disc • visual fields 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×